New combo pill beats single drug for blood pressure control
NCT ID NCT06236061
Summary
This study tested whether adding a second blood pressure medication (amlodipine) to an existing drug (LCZ696) works better than using LCZ696 alone. It involved 718 adults with mild-to-moderate high blood pressure that wasn't fully controlled on just LCZ696. The goal was to see if the combination lowers blood pressure more effectively and is safe for long-term use.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Nagoya, Aichi-ken, 4518511, Japan
-
Novartis Investigative Site
Nagoya, Aichi-ken, 453-0804, Japan
-
Novartis Investigative Site
Nagoya, Aichi-ken, 4540933, Japan
-
Novartis Investigative Site
Nagoya, Aichi-ken, 4578511, Japan
-
Novartis Investigative Site
Itoshima, Fukuoka, 8191104, Japan
-
Novartis Investigative Site
Chitose, Hokkaido, 066-0032, Japan
-
Novartis Investigative Site
Sapporo, Hokkaido, 30026, Japan
-
Novartis Investigative Site
Sapporo, Hokkaido, 630826, Japan
-
Novartis Investigative Site
Sapporo, Hokkaido, 630842, Japan
-
Novartis Investigative Site
Akashi, Hyōgo, 674-0081, Japan
-
Novartis Investigative Site
Amagasaki, Hyōgo, 660-0861, Japan
-
Novartis Investigative Site
Tsukuba, Ibaraki, 3050861, Japan
-
Novartis Investigative Site
Kamakura, Kanagawa, 247-0055, Japan
-
Novartis Investigative Site
Kawasaki-shi, Kanagawa, 211-0041, Japan
-
Novartis Investigative Site
Yokohama, Kanagawa, 231-0023, Japan
-
Novartis Investigative Site
Yokohama, Kanagawa, 232-0064, Japan
-
Novartis Investigative Site
Ōsaki, Miyagi, 989-6143, Japan
-
Novartis Investigative Site
Sendai, Miyagi, 980-0011, Japan
-
Novartis Investigative Site
Sendai, Miyagi, 9830039, Japan
-
Novartis Investigative Site
Suita, Osaka, 5650853, Japan
-
Novartis Investigative Site
Chiyoda City, Tokyo, 101-0041, Japan
-
Novartis Investigative Site
Chuo Ku, Tokyo, 104-0031, Japan
-
Novartis Investigative Site
Chuo-ku, Tokyo, 1030027, Japan
-
Novartis Investigative Site
Hachiōji, Tokyo, 192-0046, Japan
-
Novartis Investigative Site
Kiyose, Tokyo, 204-0021, Japan
-
Novartis Investigative Site
Musashino, Tokyo, 1800022, Japan
-
Novartis Investigative Site
Nerima Ku, Tokyo, 1770051, Japan
-
Novartis Investigative Site
Setagaya-ku, Tokyo, 1550031, Japan
-
Novartis Investigative Site
Shibuya City, Tokyo, 150-0013, Japan
-
Novartis Investigative Site
Shinagawa-Ku, Tokyo, 141-0032, Japan
-
Novartis Investigative Site
Shinjuku Ku, Tokyo, 160-0008, Japan
-
Novartis Investigative Site
Shinjuku-ku, Tokyo, 1600017, Japan
-
Novartis Investigative Site
Shinjuku-ku, Tokyo, 1690072, Japan
-
Novartis Investigative Site
Suginami-ku, Tokyo, 166-0003, Japan
-
Novartis Investigative Site
Toshima-Ku, Tokyo, 171-0021, Japan
-
Novartis Investigative Site
Chuoh-ku, 104-0031, Japan
-
Novartis Investigative Site
Fukuoka, 810-0021, Japan
-
Novartis Investigative Site
Hiroshima, 732-0053, Japan
-
Novartis Investigative Site
Kyoto, 615-8125, Japan
-
Novartis Investigative Site
Osaka, 5300002, Japan
-
Novartis Investigative Site
Osaka, 5320003, Japan
-
Novartis Investigative Site
Osaka, 536-0008, Japan
-
Novartis Investigative Site
Osaka, 550-0013, Japan
Conditions
Explore the condition pages connected to this study.